{
    "nctId": "NCT00454805",
    "briefTitle": "AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.",
    "officialTitle": "A Phase II, Double-Blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of AZD2171 in Combination With Fulvestrant vs Fulvestrant Alone in Hormone Sensitive (ER+ve or PgR+ve) Post Menopausal Metastatic Breast Cancer Patients",
    "overallStatus": "COMPLETED",
    "conditions": "Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 75,
    "primaryOutcomeMeasure": "Progression Free Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent\n* Females with histological/cytological confirmation of hormone sensitive breast cancer with evidence of metastatic disease\n* One or more evaluable lesions\n\nExclusion Criteria:\n\n* Prior hormonal therapy with fulvestrant\n* More than one course of prior systemic cytotoxic chemotherapy for metastatic breast cancer\n* Prior biologic therapy for ABC including Anti-VEGF agents\n* Radiation therapy within 4 weeks prior to provision of consent",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}